Events

Innovation Fund 2023 Auction Info day
NOV
Thu
30
10:00 - 12:30

This was 2 years ago

Location

Online

Programmes
Climate, Energy, Mobility

CINEA and the European Commission's DG CLIMA are organising an online info session for the Innovation Fund 2023 Auction (IF2023 Auction).

Up to €800 million is to be awarded to renewable hydrogen producers located in the European Economic Area. The auction will open on 23 November 2023. Bids can be placed until 8 February 2024.

You can find more information and register on the official announcement.

You can find more information on the auction system (called 'competitive bidding') here.

Draft agenda:

  • 10:00 - 10:25 (CET) - Welcome and introduction
    • Presentation of the Innovation Fund (CINEA)
    • Policy context (DG CLIMA)
  • 10:25 - 10:45 (CET)
    • IF23 Auction - Background and objectives
  • 10:45 - 11:20 (CET)
    • IF23 Auction - Design elements
    • Q&A
  • 11:20 - 12:25 (CET)
    • IF23 Auction - Assessment criteria
    • Q&A
  • 12:25 - 12:30 (CET)
    • Closing remarks

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.